The existing cell product candidates would just need to be paired in clinical trials with different approved therapeutic antibodies, such as trastuzumab for HER2-positive tumors, daratumumab for CD38-positive multiple myeloma (this would work for T cells but not for NK-92 cells, which are CD38-positive) and atezolizumab, avelumab or durvalumab for PD-L1-positive tumors and so forth. This evidence concerns the gene CD38 and AL amyloidosis.